The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 28.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 107% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 279%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (7 analysts) rates it none, with a mean price target of $77.
Ichor Holdings, Ltd.
ICHR · Nasdaq · USD · Market cap $2.2B · 1,891 employees
Ichor Holdings, Ltd.
PASS · Titan Ethical · score 70.0At the last full screen
2026-08-27
Screened 2026-08-27 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
This name holds its markdown label.
Ichor Holdings, Ltd. holds its Markdown at $59.09. The statistical read favours the sellers, held for 28 days.
| Phase | Markdown · caution |
| Quantitative state | The statistical read favours the sellers, held for 28 days |
| Price at the screen | $59.09 |
| Valuation | N/A trailing · 18.08 forward price to earnings |
| Values screen | PASS · score 70.0 |
| Beta | 1.86 |
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 16.99% | Below 33% | Interest-bearing debt is just 17.0% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 17.90% | Below 49% | Money owed to the company is 17.9% of assets, under the 49% limit. | Pass |
| Revenue purity | 0.00% | Below 5% | Only 0.0% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is WorthThe Fair Value Range
Fair value range in USD, drawn from the 2026-08-27 screen. The gold marker is the market price at the same screen. A 6.3% margin of safety to the base estimate.
Third-party analyst targets: 7 covering, consensus None. The average target sits +66% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsChip gear makers face brutal boom bust cycles
Picture a factory floor that hums only when chipmakers splash out on new kit, then falls silent the moment orders dry up. Ichor sits right in that supply chain, building the fluid systems that feed semiconductor tools. At $82.87 the shares already price in a recovery that has not arrived, while our fair value sits at $50.90.
The business shows none of the usual signs that would justify paying up. Forward earnings sit at 30.7 times, revenue is crawling along at 5 percent, and both profit margins and return on equity are negative. In a cyclical industry those numbers often mark peak earnings dressed up as value, not a bargain.
Ethical checks clear, yet the combination of high multiples, weak returns and exposure to semiconductor spending swings leaves no margin of safety. We pass.
Analysis, not advice.
| Forward P/E | 18.1xfairly priced for its growth rate |
| EPS, trailing | -1.17 |
| EPS, forward | 3.27 |
| Revenue growth | +22.7%strong top-line growth |
| Profit margin | -4.0%currently unprofitable |
| Return on equity | -5.2%not currently earning a positive return on equity |
| FCF yield | 0.46% |
| Debt to equity | 0.18minimal debt: a conservative balance sheet |
| Current ratio | 3.70comfortably covers its short-term bills |
| Beta | 1.86much more volatile than the market |
| Short interest, float | 0.07% |
| 52-week range | 14.06 - 113.58 |
| Market cap | $2.2B |
| Employees | 1,891 |
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeICHR trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 4.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 107% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 279%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (7 analysts) rates it none, with a mean price target of $77.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 107% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 279%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (7 analysts) rates it none, with a mean price target of $77.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $76.95 | -5.3% | · | $947 | -5.3% |
| 2 months | $57.50 | +26.8% | · | $1,268 | +26.8% |
| 3 months | $41.64 | +75.1% | · | $1,751 | +75.1% |
| 6 months | $18.69 | +290.0% | · | $3,900 | +290.0% |
| 1 year | $19.24 | +278.9% | · | $3,789 | +278.9% |
| 2 years | $37.93 | +92.2% | · | $1,922 | +92.2% |
| 3 years | $34.29 | +112.6% | · | $2,126 | +112.6% |
| 5 years | $55.16 | +32.2% | · | $1,322 | +32.2% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever ICHR does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.